Abstract
Neisseria meningitidis confronts us in a wide spectrum of diseases ranging from asymptomatic carriership to life-threatening invasive meningococcal disease. Worldwide, two types of meningococcal vaccines (polysaccharide and conjugated) are in clinical use against the disease. Polysaccharide meningococcal vaccines are preferred in countries where there is no access of conjugate vaccine in adolescents and young adults after the age of 2, who are particularly at risk for invasive meningococcal disease. As one of the conjugated meningococcal vaccines MenACWY-CRM is important since it can be used from 2 months of age. The results of the studies have shown that the MenACWY-CRM vaccine is effective and has a low side-effect profile in infants, children, adolescents and adults.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
